Comparison of Survival and Retention Rates between Infliximab and Adalimumab for Psoriasis: 10-Year Experience at a Single Tertiary Center.

Onsun, Nahide; Günes, Begüm; Kaya, Gökhan; Güçkan Isik, Bengisu; Yabaci Tak, Aysegül

Onsun, Nahide; Günes, Begüm; Kaya, Gökhan; Güçkan Isik, Bengisu; Yabaci Tak, Aysegül.

Afiliación

Onsun N; Department of Dermatology and Venereology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Günes B; Department of Dermatology and Venereology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey, begumyurtsever@yahoo.com.
Kaya G; Department of Dermatology and Venereology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Güçkan Isik B; Department of Dermatology and Venereology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Yabaci Tak A; Department of Bioistatistics, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.

Dermatology ; 239(3): 355-361, 2023.

Article en En | MEDLINE | ID: mdl-36871548

Asunto(s)

Psoriasis; Humanos; Adalimumab/uso terapéutico; Infliximab/uso terapéutico; Psoriasis/tratamiento farmacológico; Etanercept/uso terapéutico; Resultado del Tratamiento

Palabras clave

Adalimumab; Infliximab; Psoriasis; Retention

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Dermatology Asunto de la revista: DERMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google